Condition (MeSH)
Schnitzler Syndrome
ClinicalTrials.gov lists 11 trials for Schnitzler Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Schnitzler Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Schnitzler Syndrome trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2011 | 3 |
| 2009 | 2 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Schnitzler Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 8 |
| Observational | 3 |
How many Schnitzler Syndrome trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 6 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Schnitzler Syndrome trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
| Olatec Therapeutics, Inc. | 1 |
| R-Pharm Overseas, Inc. | 1 |
Which drugs are being tested for Schnitzler Syndrome? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RPH - 104 | 1 |
| Dapansutrile | 1 |
| Givinostat | 1 |
| Rilonacept | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Canakinumab, ACZ885 | 3 |
| tocilizumab SC | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Schnitzler Syndrome? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. | The journal of allergy and clinical immunology. In practice | 2021 | Yes |
| Canakinumab in Schnitzler syndrome. | Seminars in arthritis and rheumatism | 2013 | Yes |
| Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. | Annals of the rheumatic diseases | 2013 | Yes |
| Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. | Allergy | 2012 | Yes |
| Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. | Clinical rheumatology | 2010 | Yes |
Showing 5 of 14 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Schnitzler syndrome | Cases families | Worldwide | Not stated | Exact | |
| Schnitzler syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Schnitzler syndrome | Cases families | Worldwide | Not stated | Exact | |
| Schnitzler syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Schnitzler syndrome | Cases families | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Schnitzler syndrome | 37748 | Exact | Orphadata Science knowledge files, Product 1 |
| Schnitzler syndrome | 37748 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.